BIOGEN INC. (BIIB) vs VERTEX PHARMACEUTICALS INC / MA (VRTX)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | BIIB | VRTX |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $9.89B | $12B |
| Revenue growth (YoY) | ▲ 2.2% | ▲ 8.9% |
| Net income | $1.29B | $3.95B |
| Gross margin | 75.7% | 86.2% |
| Diluted EPS | $8.79 | $15.32 |
| Insider net (6 mo) | +15.7K sh • 2 sells • 0 buys | +809 sh • 14 sells • 0 buys |
| Institutional owners | 42 | 47 |
| Institutional value held | $23.28B | $86.39B |
| Next earnings (est.) | Around Oct 29, 2026 | Nov 2, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About BIOGEN INC. (BIIB)
Biogen is a global biopharmaceutical company dedicated to discovering, developing, and delivering therapies for serious and complex diseases, with a core focus on neurology, specialized immunology, and rare diseases. Read more →
About VERTEX PHARMACEUTICALS INC / MA (VRTX)
Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing transformative medicines for people with serious diseases, concentrating on specialty markets. Read more →
Source: SEC EDGAR.